You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Omniphobic cerebral shunt to eliminate clogging and dysfunction

    SBC: FreeFlow Medical Devices LLC            Topic: 106

    PROJECT SUMMARY Hydrocephalus causes long term neurological problems and patient suffering. Current treatments, most of which involve surgical diversion of cerebrospinal fluid (CSF) with shunt catheters, fail at an alarming rate. Approximately 98% of all shunts fail within 10 years, and this failure rate is the dominant contributor to the $2 billion-per-year cost that hydrocephalus incurs on our h ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a topical fixed-dose combination drug for peripheral neuropathic pain.

    SBC: WinSanTor, Inc.            Topic: NINDS

    PROJECT SUMMARY An estimated 30 million people in the United States suffer from some form of peripheral neuropathy, a condition that develops as a result of damage to the peripheral nervous system. The top two major causes of peripheral neuropathy in the US are diabetes mellitus (both T1DM and T2DM) and chemotherapeutic agents. Currently, there are no FDA-approved treatments to prevent or reverse ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Nucleotide inhibitors as precision medicine in breast cancer

    SBC: Recombination Therapeutics, LLC            Topic: 102

    Breast cancer is the most frequently diagnosed cancer in women, and 15-20% of patients have triple negative breast cancer (TNBC) which results in a 70% mortality rate within 5 years of diagnosis. 10-15% of TNBC patients possess heritable mutations in the BRCA1/BRCA2 tumor suppressor genes which promote homologous recombination (HR) of DNA double-strand breaks (DSBs). BRCA-mutated cells are highly ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Portable Affordable Innovative and Smart Device-Coupled Electronic Fetal Monitoring System to Improve Rural Access to Obstetrics Services and Improve Outcomes in Rural Communities

    SBC: Fetal Life, LLC            Topic: 102

    Obstetricians measure fetal heartrate (FHR) and uterine contractions to evaluate fetal health during pregnancy and labor. This monitoring is performed to decrease the development of complications while minimizing the need for unnecessary obstetric interventions and is especially important for women with high-risk pregnancies. However, many women, especially in rural areas, do not have the time or ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Catheter Based Cardiovascular Device Retrieval System

    SBC: Onocor LLC            Topic: NHLBI

    Recent advances in technology have made possible the treatment of a growing number of structural cardiovascular diseases by catheter based procedures. Atrial septal defects (ASD), ventricular septal defects (VSD), aortic aneurysm, congenital defects and valve disease are all currently being treated with catheter based strategies. These procedures are complex and are prone to device misplacement, e ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Intrapartum Transabdominal Fetal Pulse Oximetry: Demonstration in Ewe Models

    SBC: Storx Technologies, Inc.            Topic: NICHD

    Project Summary Despite significant cost and clear evidence of health risks associated with Cesarean section surgeries, an unnecessarily large number of infants are delivered via Cesarean section (C- Section) surgeries. The high rate of C-section in the US, relative to globally accepted norms, and the associated additional cost and complications are in part, due to high false positive rate of intr ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. A Novel, Field-Deployable, Biomimetic Narcotics Detector for the Identification of Fentanyl and Other Synthetic Opioids

    SBC: SEACOAST SCIENCE, INC.            Topic: NIDA

    AbstractThe alarming scope of the rapidly growing opioid epidemic has commanded the nation’s attention. The White House’s Council of Economic Advisers estimates that in 2015, the economic cost of the opioid crisis was over $504.0 billion (2.8% of GDP); and it is only expected to continue rising. Today, 1 in 5 fatalities amongst young adults is opioid related; with half a million fatal overdose ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Eliminating the human factor from stereotaxic surgeries

    SBC: Popneuron LLC            Topic: 104

    Project Summary: The main goal of this research project is to develop a new line of new stereotaxic devices for small animal research that outperforms existing devices in terms of accuracy, reproducibility, and ease of use. Advancing a tool such as an electrode, injection pipette or optical fiber through a small hole in the cranium, sometimes over long distances, and placing it precisely in a part ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Novel AMPK Activators for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus

    SBC: NephroDI Therapeutics, Inc.            Topic: 400

    PROJECT SUMMARYNephrogenic diabetes insipidus (NDI) is a disease characterized by the production of very large quantities of dilute urine from an inability of the kidney to respond to vasopressin. NDI can be either congenital or acquired. Acquired NDI is a common side effect of lithium therapy. Lithium-induced NDI patients produce over 3 L/d of dilute urine. Lithium is the first-line treatment for ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Functionalized perfluorocarbon nanoemulsions for enhanced cell labeling for fluorine-19 MRI detection

    SBC: CELSENSE, INC.            Topic: NIBIB

    This project aims to develop and commercialize a novel MRI probe technology for the cell therapy tools market. This project will transfer technology invented in the academic lab of Dr. Ahrens at UCSD, to Celsense, Inc., an established company that offers imaging agents for visualizing and quantifying the trafficking of cell therapies and inflammation in the body using magnetic resonance imaging (M ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government